A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.

Detlef SchuppanMarkku MäkiKnut E A LundinJorma IsolaTina Friesing-SosnikJuha TaavelaAlina PoppJari KoskenpatoJost LanghorstØistein HovdeMarja-Leena LähdeahoStefano FuscoMichael SchumannHelga P TörökJuozas KupcinskasYurdagül ZopfAnsgar W LohseMika ScheininKarin KullLuc BiedermannValerie ByrnesAndreas StallmachJørgen JahnsenJonas ZeitzRalf MohrbacherRoland Greinwaldnull null

Published in: The New England journal of medicine (2021)

In this preliminary trial, treatment with ZED1227 attenuated gluten-induced duodenal mucosal damage in patients with celiac disease. (Funded by Dr. Falk Pharma; CEC-3 EudraCT number, 2017-002241-30.).

Keyphrases

celiac disease
oxidative stress
high glucose
clinical trial
diabetic rats
study protocol
phase iii
phase ii
endothelial cells
ulcerative colitis